Pancreatic Cancer Research

ResearcherKaiser PermanenteActive in the last 2 years

Bechien U. Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-3304-2704; OpenAlex author ID A5035185848. Sources: OpenAlex.

Their work

Papers
34 (first author 1, last author 19)
Trials
0
Grants
0
Labs led
2
Collaborators
47
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 4 papers · 2021: 2 papers · 2022: 4 papers · 2023: 4 papers · 2024: 4 papers · 2025: 3 papers · 2026: 7 papers

Papers 34

  1. Surveillance Testing and Pancreatic Cancer Incidence Among Patients With Pancreatic Cysts. Co-author DOI 10.1001/jamanetworkopen.2026.27103↗
  2. Implementation of Risk Prediction Models Using Electronic Health Data for Early Detection of Pancreatic Cancer: A Prospective Pilot Feasibility Study. Co-author DOI 10.1002/cam4.72368↗
  3. Real world deployment of a pancreatic cancer risk model: impact of refitting, imputation, and computational burden. Last author DOI 10.1016/j.ebiom.2025.106118↗
  4. Knowledge, preferences, and potential barriers to additional testing among patients identified as increased risk of pancreatic cancer through machine-learning … Last author DOI 10.1016/j.pan.2026.03.017↗
  5. Risk of Pancreatic Cancer in Glycemically Defined New-Onset Diabetes: A Prospective Cohort Study. First author DOI 10.1053/j.gastro.2025.06.025↗
  6. Heuriskance: a novel paradigm for systematic earlier detection of sporadic pancreatic cancer. Co-author DOI 10.1093/jnci/djaf291↗
  7. Assessment of impending pancreatic cancer in a cohort of new onset diabetes on basis of biomarker trajectory Co-author DOI 10.64898/2026.08.06.26359908↗
  8. Tailored Strategies are Needed to Address Racial and Ethnic Disparities in Pancreatic Cancer Risk Prediction. Last author DOI 10.1016/j.gastha.2025.100657↗
  9. Identifying signs and symptoms of pancreatic cancer: a population-based study using electronic health records and natural language processing. Last author DOI 10.1016/j.pan.2025.05.005↗
  10. Risk of Pancreatic Cancer in Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator Germline Variants: A Retrospective Cohort Study. Last author DOI 10.14309/ctg.0000000000000857↗
  11. Early features of pancreatic cancer on magnetic resonance imaging (MRI): a case-control study. Last author DOI 10.1007/s00261-024-04271-2↗
  12. Prediction of pancreatic cancer in patients with new onset hyperglycemia: A modified ENDPAC model. Last author DOI 10.1016/j.pan.2024.09.015↗
  13. Association of Glycated Hemoglobin With a Risk of Pancreatic Cancer in High-Risk Individuals Based on Genetic and Family History. Co-author DOI 10.14309/ctg.0000000000000650↗
  14. Identifying Symptoms Prior to Pancreatic Ductal Adenocarcinoma Diagnosis in Real-World Care Settings: Natural Language Processing Approach. Co-author DOI 10.2196/51240↗
  15. Machine learning versus regression for prediction of sporadic pancreatic cancer. Last author DOI 10.1016/j.pan.2023.04.009↗
  16. Risk Prediction of Pancreatic Cancer in Patients With Recent-onset Hyperglycemia: A Machine-learning Approach. Last author DOI 10.1097/mcg.0000000000001710↗
  17. Derivation and External Validation of Machine Learning-Based Model for Detection of Pancreatic Cancer. Last author DOI 10.14309/ajg.0000000000002050↗
  18. Quantitative Radiomic Features From Computed Tomography Can Predict Pancreatic Cancer up to 36 Months Before Diagnosis. Last author DOI 10.14309/ctg.0000000000000548↗
  19. Early Detection Initiative: A randomized controlled trial of algorithm-based screening in patients with new onset hyperglycemia and diabetes for early detectio… Co-author DOI 10.1016/j.cct.2021.106659↗
  20. Risk Prediction of Pancreatic Cancer in Patients With Abnormal Morphologic Findings Related to Chronic Pancreatitis: A Machine Learning Approach. Last author DOI 10.1016/j.gastha.2022.06.008↗
  21. Clinical and Imaging Predictors of Pancreatic Cancer in Patients Hospitalized for Acute Pancreatitis. Last author DOI 10.1016/j.gastha.2022.07.009↗
  22. Predicting pancreatic ductal adenocarcinoma using artificial intelligence analysis of pre-diagnostic computed tomography images. Co-author DOI 10.3233/cbm-210273↗
  23. Validation of the Enriching New-Onset Diabetes for Pancreatic Cancer Model in a Diverse and Integrated Healthcare Setting. Last author DOI 10.1007/s10620-020-06139-z↗
  24. Diabetes and pancreatic cancer: recent insights with implications for early diagnosis, treatment and prevention. Co-author DOI 10.1097/mog.0000000000000763↗
  25. Association of Glycated Hemoglobin Levels With Risk of Pancreatic Cancer. Co-author DOI 10.1001/jamanetworkopen.2020.4945↗
  26. New-Onset Diabetes, Longitudinal Trends in Metabolic Markers, and Risk of Pancreatic Cancer in a Heterogeneous Population. Co-author DOI 10.1016/j.cgh.2019.11.043↗
  27. Prediction of Pancreatic Cancer Based on Imaging Features in Patients With Duct Abnormalities. Last author DOI 10.1097/mpa.0000000000001499↗
  28. Identification of Individuals at Increased Risk for Pancreatic Cancer in a Community-Based Cohort of Patients With Suspected Chronic Pancreatitis. Last author DOI 10.14309/ctg.0000000000000147↗
  29. Do changes in health reveal the possibility of undiagnosed pancreatic cancer? Development of a risk-prediction model based on healthcare claims data. Co-author DOI 10.1371/journal.pone.0218580↗
  30. Impact of Integrated Health Care Delivery on Racial and Ethnic Disparities in Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000000981↗
  31. Cachexia, and not obesity, prior to pancreatic cancer diagnosis worsens survival and is negated by chemotherapy. Last author DOI 10.21037/jgo.2017.11.10↗
  32. Influence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer. Last author DOI 10.1093/jnci/djw275↗
  33. Impact of statin use on survival in patients undergoing resection for early-stage pancreatic cancer. Co-author DOI 10.1038/ajg.2015.217↗
  34. The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-medicare analysis. Co-author DOI 10.1371/journal.pone.0121783↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wansu Chen · 17 shared papers, 2020–2026 · strength 3.74
  2. Tiffany Q. Luong · 12 shared papers, 2022–2026 · strength 3.23
  3. Christie Y. Jeon · 10 shared papers, 2015–2026 · strength 1.52
  4. Fagen Xie · 6 shared papers, 2023–2025 · strength 1.42
  5. Suresh T. Chari · 7 shared papers, 2020–2026 · strength 1.38
  6. Lynn McCormick Matrisian · 5 shared papers, 2022–2026 · strength 1.17
  7. Anirban Maitra · 5 shared papers, 2022–2026 · strength 1.10
  8. Ziding Feng · 4 shared papers, 2022–2026 · strength 0.89
  9. Barbara J. Kenner · 3 shared papers, 2022–2026 · strength 0.66
  10. Ying‐Qi Zhao · 3 shared papers, 2022–2026 · strength 0.66
  11. Stephen Jacob Pandol · 6 shared papers, 2015–2022 · strength 0.58
  12. Jo Ann Rinaudo · 3 shared papers, 2022–2026 · strength 0.56
  13. William E Fisher · 2 shared papers, 2026 · strength 0.52
  14. Brian Z. Huang · 5 shared papers, 2015–2020 · strength 0.50
  15. Phil A. Hart · 2 shared papers, 2026 · strength 0.45
  16. Avinash R. Kambadakone · 2 shared papers, 2022–2026 · strength 0.44
  17. Jonathan I. Chang · 4 shared papers, 2015–2018 · strength 0.38
  18. Nikita J. Patel · 1 shared paper, 2025 · strength 0.37
  19. Kush Yadav · 1 shared paper, 2026 · strength 0.30
  20. Eric E. Chiang · 1 shared paper, 2026 · strength 0.27
  21. Joseph R. Pisegna · 2 shared papers, 2019–2023 · strength 0.26
  22. Rex A. Parker · 1 shared paper, 2024 · strength 0.26
  23. Syed Ajaz Ahmed · 1 shared paper, 2024 · strength 0.24
  24. Matthew R. Young · 1 shared paper, 2026 · strength 0.23
  25. Ehsan Irajizad · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.